Adverum Biotech



Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.

Peter Soparkar
Brigit Riley
Chief Scientific Officer
Julie Clark
Chief Medical Officer
Jim Wang
SVP, Head of Regulatory Affairs
Dena House
Carla Fiankan
VP, Regulatory Affairs
Thomas Kochy
VP, Commercial & Program Strategy
Claire M. Gelfman
Executive Director, Pharmaceutical Development

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.